Teladoc Health Inc.
TDOC-
Teladoc Health dropped 22% to $15.98 after the online health service provider reported weaker-than-expected quarterly revenue.
Revenue in the fourth quarter increased 4% to $660.5 million from $637.7 million, net loss shrank to $28.9 million from $3.8 billion, and diluted loss per share fell to 17 cents from $23.49 a year ago.
Results for the fourth quarter of 2022 primarily included non-cash goodwill impairment charges of $3.77 billion, or $23.26 per share, stock-based compensation expense of $50.8 million, or $0.31 per share, and amortization of acquired intangibles of $50.2 million, or $0.31 per share.
Net loss for the fourth quarter of 2022 also included $3.7 million, or $0.02 per share, of restructuring costs primarily related to the abandonment of certain excess leased office space.
Feb 21, 2024 -
Teladoc Health Inc soared 25.5% to $28.60 after the online healthcare provider reported better-than-expected quarterly results.
Revenue in the second quarter increased 10% to $652.4 million and net loss shrank to $65 million from $3.1 billion and diluted loss per share fell to 40 cents from $19.22 a year ago.
The prior year's quarter included a non-cash goodwill charge of $3.03 billion or $18.78 a share.
The company guided revenue in the third quarter between $650 million and $675 million and net loss per share between 50 cents and 40 cents and membership level at about 86 million.
The online healthcare provider estimated revenue for the full-year 2023 between $2.6 billion and $2.675 billion and diluted loss per share between $1.25 and $1.60.
Jul 26, 2023 -
Teladoc Health Inc rose 5% to $27.02 after the telehealth platform operator lifted its revenue and adjusted earnings outlook for the year.
Revenue in the first quarter increased 11% to $629.2 million and net loss in the quarter dropped to $69 million from $6.7 billion and diluted loss per share fell to 42 cents to $41.58 a year ago.
In the first quarter of 2022, the company recorded a goodwill impairment charge of $6.6 billion.
The telemedicine company forecasted second quarter revenue between $635 million and $660 million and between $2.575 billion and $2.675 billion in the full-year 2023.
The company also estimated adjusted operating earnings between $60 million and $68 million in the second quarter and between $285 million and $325 million in the full-year 2023.
Apr 27, 2023
|
|
| |
|
| Trading Volume | 102,450 |
|
|
22.97 - 6.85 |
| Market Cap Full | $ 1.2B |
Quarterly +
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Q1 | -46% | 4.6% | -30% | 9.5% |
| Q2 | - | 84.5% | -31.8% | -2.2% |
| Q3 | - | 84.5% | -13.5% | -26.6% |
| Q4 | - | 84.5% | -4.3% | 16.9% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2025 | |||||||||||
| 4.6 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| -9.9 | -22.4 | - | -13.9 | -13.4 | -9.9 | -18.7 | -13.5 | - | - | - | -24 |
| 2023 | |||||||||||
| 24.4 | -9.9 | -2.3 | 2.5 | -12.8 | 9.4 | 17.6 | -23.9 | -18 | -11 | 9.7 | 18.7 |
| 2022 | |||||||||||
| -16.5 | -1.3 | -4.7 | -53.2 | 1 | -2.6 | 11 | -16.1 | -18 | 16.9 | -3.8 | -17.1 |
| 2021 | |||||||||||
| 33.7 | -16.2 | -17.8 | -5.2 | -12.6 | 10.4 | -10.7 | -2.7 | -11.1 | 16.5 | -32.3 | -9.3 |
EPS
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Q1 | -0.4 | 0 | 0 |
| Q2 | -0.4 | 0 | 0 |
| Q3 | -0.4 | 0 | 0 |
| Q4 | 0 | -23.4 | -2.7 |
| A | -1.17 | -84.6 | -2.7 |